Author/Authors :
Hamidizadeh, Nasrin Skin Research Center - Shohada-e- Tajrish Hospital - Shahid Beheshti University of Medical Sciences, Tehran , Barikbin, Behrooz Skin Research Center - Shohada-e- Tajrish Hospital - Shahid Beheshti University of Medical Sciences, Tehran , Yousefi, Maryam Skin Research Center - Shohada-e- Tajrish Hospital - Shahid Beheshti University of Medical Sciences, Tehran , Sahraei, Abbas Skin Research Center - Shohada-e- Tajrish Hospital - Shahid Beheshti University of Medical Sciences, Tehran , Khamesipour, Ali Center for Research and Training in Skin Disease and Leprosy - Tehran University of Medical Sciences, Tehran , Younespour, Shima Skin Research Center - Shohada-e- Tajrish Hospital - Shahid Beheshti University of Medical Sciences, Tehran , Sadeghitehrani, Hanif Biomedical Radiation Science Center - Department of Oncology - Radiology and Clinical immunology - Faculty of Medicine - Uppsala University, Sweden
Abstract :
Introduction: Cutaneous Leishmaniasis (CL) is a parasitic disease caused by Leishmania species. Currently accessible treatments remain insufficient, and there is pressure to develop suitable and effectual options. In this study, we used different concentrations of podophyllin in vitro on leishmania parasites and then on leishmaniasis lesions in mice and compared their efficacy.
Method: We used podophyllin (14.3 μg/ml) in vitro against
leishmania major parasites, then in experimental animals in
different concentrations.
Results: Podophyllin (14.3 μg/ml) that used in vitro eradicated
leishmania major parasites, but, in mice after four weeks was
not effective and the diameter of the lesions increase with use
of topical podophyllin.
Conclusion: Despite the lethal effect on leishmania in vitro,
treatment with different doses of podophyllin could not
accelerate the healing process of the leishmaniasis lesions of the experimental rats.
Keywords :
leishmaniasis , podophyllin , treatment , in vitro
